Finance
2023.12.05
Lumosa’s Lead Candidate LT3001 for Acute Ischemic Stroke Approaching Key Milestone, Targeting Unblinding in Late 2024
Corporate
2023.09.26
Lumosa Partner, AMed Co., Informed the Receipt of Market Authorization from Brunei (BDMCA), for Naldebain, an Extended-Release Analgesic Injection
Corporate
2023.07.26
LT3001 Received Formulation Patent from USPTO
Corporate
2023.05.15
Lumosa’s LT1001 Received First European Approval from Ukraine’s SMDC
Corporate
2023.04.19
First subject for LT3001 Phase 2 trial enrolled in China
Corporate
2023.03.20
Lumosa team to attend STAIR XII